U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H26ClN3O3.ClH
Molecular Weight 404.331
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUCALOPRIDE HYDROCHLORIDE

SMILES

Cl.COCCCN1CCC(CC1)NC(=O)C2=CC(Cl)=C(N)C3=C2OCC3

InChI

InChIKey=KKMOQGWTJRGLNN-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O3.ClH/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;/h11-12H,2-10,20H2,1H3,(H,21,23);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H26ClN3O3
Molecular Weight 367.87
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESOLOR
PubMed

PubMed

TitleDatePubMed
Gateways to clinical trials.
2002 Oct
Prucalopride: the evidence for its use in the treatment of chronic constipation.
2008 Jun
[Functional and motor gastrointestinal disorders].
2008 Oct
Gateways to clinical trials.
2008 Oct
Prucalopride.
2009
Gateways to clinical trials.
2009 Apr
Prucalopride: a new drug for the treatment of chronic constipation.
2009 Aug
Gateways to clinical trials.
2009 Dec
Prucalopride for chronic constipation.
2009 Dec
Translating 5-HT receptor pharmacology.
2009 Dec
Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study.
2009 Dec
Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach.
2009 Jan
Motility: prucalopride for chronic constipation.
2009 Jun
Gateways to clinical trials.
2009 Mar
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
2009 May
Investigations into the binding affinities of different human 5-HT4 receptor splice variants.
2010
Comments on tegaserod trial on irritable bowel syndrome.
2010 Apr
Effect of ICU interventions on gastrointestinal motility.
2010 Apr
Update on the management of constipation in the elderly: new treatment options.
2010 Aug 9
Prucalopride for constipation.
2010 Feb
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.
2010 Feb
Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.
2010 Feb 16
[New drugs for the treatment of constipation].
2010 Jul
New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
2010 Jun
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
2010 Jun 8
Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice.
2010 Mar 4
Influence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis.
2010 May
Emerging pharmacologic therapies for irritable bowel syndrome.
2010 Oct
Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.
2010 Oct
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
2010 Sep
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation.
2010 Sep
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Adults: 2 mg once daily with or without food, at any time of the day.
Route of Administration: Oral
In Vitro Use Guide
Cell shortening and real-time Ca(2+) measurements were processed on field-stimulated intact cardiomyocytes with the selective 5-HT4R agonist, prucalopride (1 uM).
Substance Class Chemical
Created
by admin
on Tue Oct 22 13:38:57 UTC 2019
Edited
by admin
on Tue Oct 22 13:38:57 UTC 2019
Record UNII
M8IYX9Z79V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRUCALOPRIDE HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
4-AMINO-5-CHLORO-2,3-DIHYDRO-N-(1-(3-METHOXYPROPYL)-4-PIPERIDINYL)-7-BENZOFURANCARBOXAMIDE HYDROCHLORIDE
Systematic Name English
PRUCALOPRIDE HYDROCHLORIDE [MART.]
Common Name English
PRUCALOPRIDE HYDROCHLORIDE [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
9931054
Created by admin on Tue Oct 22 13:38:57 UTC 2019 , Edited by admin on Tue Oct 22 13:38:57 UTC 2019
PRIMARY
EVMPD
SUB79171
Created by admin on Tue Oct 22 13:38:57 UTC 2019 , Edited by admin on Tue Oct 22 13:38:57 UTC 2019
PRIMARY
CAS
179474-80-7
Created by admin on Tue Oct 22 13:38:57 UTC 2019 , Edited by admin on Tue Oct 22 13:38:57 UTC 2019
PRIMARY
EPA CompTox
179474-80-7
Created by admin on Tue Oct 22 13:38:57 UTC 2019 , Edited by admin on Tue Oct 22 13:38:57 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY